Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

Exclusion Criteria

• •Clinically-significant illness (other than HCV, inherited bleeding disorder or HIV-1) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
• •Current or prior history of any of the following:
• •* Hepatic decompensation
• •* Chronic liver disease of a non-HCV etiology
• •* Hepatocellular carcinoma (HCC)
• •* Infection with hepatitis B virus (HBV)
• •Pregnant or nursing female
• •Prior treatment with inhibitors of nonstructural protein 5A (NS5A) or the NS5B polymerase
• •Chronic use of systemically administered immunosuppressive agents
• •For HIV-1/HCV co-infected individuals:
• •* Opportunistic infection within 6 months prior to screening
• •* Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline